LIVIVO - Search results -

Search results

Result 1 - 10 of total 53

Search options

Article: Progress in drug delivery and diagnostic applications of carbon dots: a systematic review.

Kaurav, Hemlata / Verma, Dhriti / Bansal, Amit / Kapoor, Deepak N / Sheth, Sandeep

2023 Volume 11, Page(s) 1227843

Abstract: Carbon dots (CDs), which have particle size of less than 10 nm, are carbon-based nanomaterials that are used in a wide range of applications in the area of novel drug delivery in cancer, ocular diseases, infectious diseases, and brain disorders. CDs are ... ...

Abstract	Carbon dots (CDs), which have particle size of less than 10 nm, are carbon-based nanomaterials that are used in a wide range of applications in the area of novel drug delivery in cancer, ocular diseases, infectious diseases, and brain disorders. CDs are biocompatible, eco-friendly, easy to synthesize, and less toxic with excellent chemical inertness, which makes them very good nanocarrier system to deliver multi-functional drugs effectively. A huge number of researchers worldwide are working on CDs-based drug delivery systems to evaluate their versatility and efficacy in the field of pharmaceuticals. As a result, there is a tremendous increase in our understanding of the physicochemical properties, diagnostic and drug delivery aspects of CDs, which consequently has led us to design and develop CDs-based theranostic system for the treatment of multiple disorders. In this review, we aim to summarize the advances in application of CDs as nanocarrier including gene delivery, vaccine delivery and antiviral delivery, that has been carried out in the last 5 years.
Language	English
Publishing date	2023-07-14
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2711776-5
ISSN	2296-2646
ISSN	2296-2646
DOI	10.3389/fchem.2023.1227843
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Progress in drug delivery and diagnostic applications of carbon dots

Hemlata Kaurav / Dhriti Verma / Amit Bansal / Deepak N. Kapoor / Sandeep Sheth

Frontiers in Chemistry, Vol

a systematic review

2023 Volume 11

Abstract	Carbon dots (CDs), which have particle size of less than 10 nm, are carbon-based nanomaterials that are used in a wide range of applications in the area of novel drug delivery in cancer, ocular diseases, infectious diseases, and brain disorders. CDs are biocompatible, eco-friendly, easy to synthesize, and less toxic with excellent chemical inertness, which makes them very good nanocarrier system to deliver multi-functional drugs effectively. A huge number of researchers worldwide are working on CDs-based drug delivery systems to evaluate their versatility and efficacy in the field of pharmaceuticals. As a result, there is a tremendous increase in our understanding of the physicochemical properties, diagnostic and drug delivery aspects of CDs, which consequently has led us to design and develop CDs-based theranostic system for the treatment of multiple disorders. In this review, we aim to summarize the advances in application of CDs as nanocarrier including gene delivery, vaccine delivery and antiviral delivery, that has been carried out in the last 5 years.
Keywords	carbon dots ; drug delivery ; gene delivery ; nanocarriers ; bioimaging ; Chemistry ; QD1-999
Subject code	610
Language	English
Publishing date	2023-07-01T00:00:00Z
Publisher	Frontiers Media S.A.
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Heart transplantation for pediatric foreign nationals in the United States.

Harano, Takashi / Sheth, Megha / Sasaki, Kazunari / Yu, Jeremy / Wightman, Sean C / Atay, Scott M / Sainathan, Sandeep / Kim, Anthony W

Clinical transplantation

2023 Volume 37, Issue 2, Page(s) e14900

Abstract: Background: This study aimed to clarify survival outcomes, waitlist mortality, and waitlist days of heart transplantation of pediatric foreign nationals compared to pediatric United States (US) citizens.: Methods: We retrieved data from March 2012 to ...

Abstract	Background: This study aimed to clarify survival outcomes, waitlist mortality, and waitlist days of heart transplantation of pediatric foreign nationals compared to pediatric United States (US) citizens. Methods: We retrieved data from March 2012 to June 2021 in the United Network Organ Sharing (UNOS) registry. Results: Of 5857 pediatric patients newly waitlisted, 133 (2.27%) patients were non-US citizen/non-US residents (non-citizen non-resident [NCNR]). Patients with congenital heart disease were higher in the US citizen group than in the NCNR group (51.9% vs. 22.6%, p < .001); 76.7% of patients in the NCNR group (102/133) had cardiomyopathy. Of the 133 NCNRs, 111 patients (83.5%) underwent heart transplantation, which was significantly higher than that in the US citizen group (68.6%, p < .001). The median waitlist time was 71 days (IQR, 22-172 days) in the NCNR group and 74 days (29-184 days) in the US citizen group (p = .48). Survival after heart transplant was significantly better in the NCNR group than in the US citizen group (n = 3982; logrank test p = .015). Conclusions: Heart transplantation for pediatric foreign nationals was mostly indicated for cardiomyopathy, and their transplant rate was significantly higher than that in the US citizen group, with better survival outcomes. The better survival outcomes in the NCNR group compared to the US citizen group can likely be attributed to the differing diagnoses for which transplantation was performed.
MeSH term(s)	Humans ; Child ; United States ; Heart Transplantation ; Heart Defects, Congenital ; Students ; Transplants ; Waiting Lists
Language	English
Publishing date	2023-01-11
Publishing country	Denmark
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	639001-8
ISSN	1399-0012 ; 0902-0063
ISSN (online)	1399-0012
ISSN	0902-0063
DOI	10.1111/ctr.14900
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2204: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Transient Receptor Potential Channels and Auditory Functions.

Ramkumar, Vickram / Sheth, Sandeep / Dhukhwa, Asmita / Al Aameri, Raheem / Rybak, Leonard / Mukherjea, Debashree

Antioxidants & redox signaling

2021 Volume 36, Issue 16-18, Page(s) 1158–1170

Abstract: Significance: ...

Abstract	Significance:
MeSH term(s)	Aminoglycosides/adverse effects ; Animals ; Capsaicin/adverse effects ; Cisplatin/adverse effects ; Hearing Loss/metabolism ; Inflammation/metabolism ; Mammals/metabolism ; Ototoxicity ; Transient Receptor Potential Channels
Chemical Substances	Aminoglycosides ; Transient Receptor Potential Channels ; Cisplatin (Q20Q21Q62J) ; Capsaicin (S07O44R1ZM)
Language	English
Publishing date	2021-12-31
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, N.I.H., Extramural
ZDB-ID	1483836-9
ISSN	1557-7716 ; 1523-0864
ISSN (online)	1557-7716
ISSN	1523-0864
DOI	10.1089/ars.2021.0191
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5488: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: "Window of Opportunity" in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports.

Surenkhuu, Bayasgalan / Mun, Christine S / Kim, Christian / Atassi, Nour Yanna / Mun, Jessica / Dhall, Nikhil / Abdel-Hadi, Sarah / Sheth, Tanya / Dondeti, Priyanka / Bernal, Alexandria / Pradeep, Anubhav / Rondelli, Damiano / Jain, Sandeep

Eye & contact lens

2024 Volume 50, Issue 5, Page(s) 222–232

Abstract: Objective: To perform a longitudinal study for determining the development of ocular graft-versus-host disease (oGVHD) after allogeneic hematopoietic stem cell transplant (HSCT) and report cases that illustrate the "window of opportunity" concept in ... ...

Abstract	Objective: To perform a longitudinal study for determining the development of ocular graft-versus-host disease (oGVHD) after allogeneic hematopoietic stem cell transplant (HSCT) and report cases that illustrate the "window of opportunity" concept in oGVHD treatment. Methods: Patients (n=61) were examined at prescheduled clinic visits before HSCT and three-month intervals after HSCT for 2 years. The presence or absence of oGVHD was determined using the international chronic oGVHD consensus group diagnostic criteria. Ocular surface washings (OSW) were obtained at each visit and analyzed for cytokine levels. Results: In the longitudinal study, 26.2% (n=16; progressed group) developed either probable (11.5%, n=7) or definite oGVHD (14.8%, n=9). In the progressed group, clinically significant changes in signs (corneal staining and Schirmer I test) and symptoms at the post-HSCT visit as compared with the pre-HSCT visit occurred at 9 months. Significant differences in clinical signs and symptoms (whether average post-HSCT values or changes in values over pre-HSCT levels) between the progressed and nonprogressed groups occurred at a 9-month visit or later. In the progressed group, 55.6% of eyes that had negative matrix metalloproteinase 9 (MMP-9) test at pre-HSCT turned MMP-9 positive at 3 to 6 months post-HSCT. In the progressed group, interleukin 8 levels in OSW were significantly increased at 6 months post-HSCT. In the case reports, the "window of opportunity" was detected by MMP-9 turning positive, early corneal staining, interleukin 8 increase in OSW, and peripheral corneal epithelial thinning, which resolved with treatment initiation. Conclusions: A "window of opportunity" exists before patients developing symptomatic tear-deficient dry eye after HSCT for initiating treatment that may preempt oGVHD development; however, larger-scale longitudinal studies are needed for definitive recommendations.
MeSH term(s)	Humans ; Dry Eye Syndromes/etiology ; Dry Eye Syndromes/therapy ; Dry Eye Syndromes/diagnosis ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/therapy ; Hematopoietic Stem Cell Transplantation ; Longitudinal Studies
Language	English
Publishing date	2024-03-13
Publishing country	United States
Document type	Journal Article ; Case Reports
ZDB-ID	2103049-2
ISSN	1542-233X ; 1542-2321
ISSN (online)	1542-233X
ISSN	1542-2321
DOI	10.1097/ICL.0000000000001081
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1724: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recombinant Deoxyribonuclease I Eye Drops for Ocular Graft Versus Host Disease: Results of a Randomized Clinical Trial.

Mun, Christine S / Surenkhuu, Bayasgalan / Chen, Yi-Fan / Atassi, Nour / Mun, Jessica / Kim, Christian / Sheth, Tanya / Sarwar, Monazzah Akbar / Pradeep, Anubhav / Jain, Sandeep

Eye & contact lens

2024 Volume 50, Issue 5, Page(s) 233–240

Abstract: Objective: We have previously shown that neutrophil extracellular traps (NETs) are present on the ocular surface of patients with ocular graft versus host disease (oGVHD), contributing to inflammation and surface disease. Therefore, we performed a ... ...

Abstract	Objective: We have previously shown that neutrophil extracellular traps (NETs) are present on the ocular surface of patients with ocular graft versus host disease (oGVHD), contributing to inflammation and surface disease. Therefore, we performed a clinical trial using deoxyribonuclease I (DNAase) eye drops to test the hypothesis that reducing the abundance of NETs from the ocular surface will reduce signs and symptoms of oGVHD. Methods: A prospective, phase I or II, randomized, placebo-controlled, double-masked clinical trial was performed to determine the safety and preliminary efficacy of DNAase (0.1%) eye drops four times daily for 8 weeks in patients with oGVHD (n=58). Intent-to-treat analysis was performed to determine the change in safety outcome measures (drug tolerability and proportion of adverse events) and efficacy outcome measures (ocular surface disease index [OSDI] score and corneal staining) between baseline and week 8. Results: Tolerability and adverse events were similar in the vehicle and DNAase groups. Within the DNAase group (but not the vehicle group), corneal staining showed a statistically significant and clinically meaningful reduction at week 8 (3.50 [2.75; 5.00]) compared with baseline (5.00 [3.00; 7.00]). The OSDI score also showed a statistically significant clinically meaningful reduction of 18.4 (9.16; 33.1) ( P <0.001) at week 8 compared with baseline (45.5 [31.8; 50.0]) within the DNAase group. The proportion of eyes that had improvement in subjective global assessment (SGA) and mucous discharge was significantly greater in the DNAase group (55.6% and 57.7% at weeks 4 and 8, respectively; P <0.0001 at both time points) as compared with the vehicle group (35.7% and 34.0% at weeks 4 and 8, respectively). Conclusions: Treatment of patients with oGVHD using DNAase eye drops is safe and demonstrates preliminary efficacy. Deoxyribonuclease I eye drops can potentially reduce the severity of signs and symptoms of ocular surface disease in patients with oGVHD.
MeSH term(s)	Humans ; Deoxyribonuclease I/therapeutic use ; Deoxyribonuclease I/administration & dosage ; Male ; Double-Blind Method ; Female ; Adult ; Middle Aged ; Prospective Studies ; Ophthalmic Solutions ; Graft vs Host Disease/drug therapy ; Young Adult ; Aged ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use ; Extracellular Traps/drug effects ; Treatment Outcome ; Adolescent
Chemical Substances	Deoxyribonuclease I (EC 3.1.21.1) ; Ophthalmic Solutions ; Recombinant Proteins
Language	English
Publishing date	2024-02-23
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Clinical Trial, Phase I ; Clinical Trial, Phase II
ZDB-ID	2103049-2
ISSN	1542-233X ; 1542-2321
ISSN (online)	1542-233X
ISSN	1542-2321
DOI	10.1097/ICL.0000000000001078
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1724: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.

Dhukhwa, Asmita / Al Aameri, Raheem F H / Sheth, Sandeep / Mukherjea, Debashree / Rybak, Leonard / Ramkumar, Vickram

Scientific reports

2021 Volume 11, Issue 1, Page(s) 8116

Abstract: Regulators of G protein signaling (RGS) accelerate the GTPase activity of G proteins to enable rapid termination of the signals triggered by G protein-coupled receptors (GPCRs). Activation of several GPCRs, including cannabinoid receptor 2 (CB2R) and ... ...

Abstract	Regulators of G protein signaling (RGS) accelerate the GTPase activity of G proteins to enable rapid termination of the signals triggered by G protein-coupled receptors (GPCRs). Activation of several GPCRs, including cannabinoid receptor 2 (CB2R) and adenosine A
MeSH term(s)	Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Cell Line ; Cisplatin/adverse effects ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Cochlea/cytology ; Cochlea/metabolism ; Gene Expression/drug effects ; Hearing Loss/diagnosis ; Hearing Loss/etiology ; Male ; Neoplasms/drug therapy ; RGS Proteins/antagonists & inhibitors ; RGS Proteins/genetics ; RGS Proteins/metabolism ; RNA Interference ; RNA, Small Interfering/metabolism ; Rats ; Rats, Wistar ; STAT1 Transcription Factor/metabolism ; STAT3 Transcription Factor/metabolism ; Signal Transduction/drug effects
Chemical Substances	Antineoplastic Agents ; RGS Proteins ; RNA, Small Interfering ; Rgs17 protein, rat ; STAT1 Transcription Factor ; STAT3 Transcription Factor ; Stat1 protein, rat ; Stat3 protein, rat ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2021-04-14
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-021-87387-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Awareness about effects of tobacco and areca-nut use in school children of Ahmedabad, India: A cross-sectional questionnaire-based survey.

Rangey, Priya Singh / Sheth, Megha Sandeep / Khan, Azizfatema

Tobacco prevention & cessation

2018 Volume 4, Page(s) 34

Abstract: Introduction: Tobacco use usually starts in the adolescent age group and continues in adulthood. This study's aim was to identify knowledge regarding the adverse effects of tobacco and areca-nut use among high school children of Ahmedabad, India.: ... ...

Abstract	Introduction: Tobacco use usually starts in the adolescent age group and continues in adulthood. This study's aim was to identify knowledge regarding the adverse effects of tobacco and areca-nut use among high school children of Ahmedabad, India. Methods: An anonymous self-administered close-ended questionnaire was designed for the study. Principals of 9 schools, 3 municipal and 6 government-aided, were approached and written informed consent was obtained. A total of 3055 students studying in grades 7-12 were included. Data were analyzed using Microsoft Excel and SPSS 16.0. Chi-squared test was applied to investigate any differences between the responses of consumers and non-consumers, while Cramer's V was applied to analyze the strength of association between the awareness of ill-effects and tobacco product consumption. Results: Of the 3055 children, 3% felt that tobacco use was definitely not harmful to health while 84% felt that it was. In all, 65% of respondents were aware that tobacco use caused cancer, 7% answered that it caused breathing problems, 5% said it caused heart problems, 0.3% answered that it caused paralysis, 4.3% felt it caused no health problems, whereas 18% thought that it caused multiple issues. With regards to the role of media, 78% had seen many anti-smoking warnings in the media, 15% had seen a few, 5% had seen none. There was a statistically significant difference between the tobacco users and and non-users with regards to exposure to media (p<0.001), discussions in class (p<0.001) and general awareness (p<0.001), but a weak association between awareness and tobacco consumption was identified (p<0.05). Conclusions: Awareness about the harmful effects of tobacco is high among school children of Ahmedabad, though use may still be prevalent.
Language	English
Publishing date	2018-10-24
Publishing country	Greece
Document type	Journal Article
ISSN	2459-3087
ISSN (online)	2459-3087
DOI	10.18332/tpc/98967
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Essentials for Pathological Evaluation of Peritoneal Surface Malignancies and Synoptic Reporting of Cytoreductive Surgery Specimens-A review and evidence-based guide.

Bhatt, Aditi / Mishra, Suniti / Parikh, Loma / Sheth, Sandeep / Gorur, Imran

Indian journal of surgical oncology

2019 Volume 11, Issue 1, Page(s) 101–126

Abstract: Peritoneal surface oncology has emerged as a subspecialty of surgical oncology, with the growing popularity of surgical treatment of peritoneal metastases comprising of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). ... ...

Abstract	Peritoneal surface oncology has emerged as a subspecialty of surgical oncology, with the growing popularity of surgical treatment of peritoneal metastases comprising of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Pathological evaluation plays a key role in multidisciplinary management but there are still many areas where there are no guidelines or consensus on reporting. Some tumors presenting to a peritoneal surface oncology unit are rare and pathologists my not be familiar with diagnosing and classifying those. In this manuscript, we have reviewed the evidence regarding various aspects of histopathological evaluation of peritoneal tumors. It includes establishing a diagnosis, appropriate classification and staging of common and rare tumors and evaluation of pathological response to chemotherapy. In many instances, the information captured is of prognostic value alone with no direct therapeutic implications. But proper capturing of such information is vital for generating evidence that will guide future treatment trends and research. There are no guidelines/data set for reporting cytoreductive surgery specimens. Based on the authors' experience, a format for handling/grossing and synoptic reporting of these specimens is provided.
Language	English
Publishing date	2019-03-19
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2568289-1
ISSN	0976-6952 ; 0975-7651
ISSN (online)	0976-6952
ISSN	0975-7651
DOI	10.1007/s13193-019-00897-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Targeting CXCL1 chemokine signaling for treating cisplatin ototoxicity.

Al Aameri, Raheem F H / Alanisi, Entkhab M A / Oluwatosin, Adu / Al Sallami, Dheyaa / Sheth, Sandeep / Alberts, Ian / Patel, Shree / Rybak, Leonard P / Ramkumar, Vickram

Frontiers in immunology

2023 Volume 14, Page(s) 1125948

Abstract: Cisplatin is chemotherapy used for solid tumor treatment like lung, bladder, head and neck, ovarian and testicular cancers. However, cisplatin-induced ototoxicity limits the utility of this agent in cancer patients, especially when dose escalations are ... ...

Abstract	Cisplatin is chemotherapy used for solid tumor treatment like lung, bladder, head and neck, ovarian and testicular cancers. However, cisplatin-induced ototoxicity limits the utility of this agent in cancer patients, especially when dose escalations are needed. Ototoxicity is associated with cochlear cell death through DNA damage, the generation of reactive oxygen species (ROS) and the consequent activation of caspase, glutamate excitotoxicity, inflammation, apoptosis and/or necrosis. Previous studies have demonstrated a role of CXC chemokines in cisplatin ototoxicity. In this study, we investigated the role of CXCL1, a cytokine which increased in the serum and cochlea by 24 h following cisplatin administration. Adult male Wistar rats treated with cisplatin demonstrated significant hearing loss, assessed by auditory brainstem responses (ABRs), hair cell loss and loss of ribbon synapse. Immunohistochemical studies evaluated the levels of CXCL1 along with increased presence of CD68 and CD45-positive immune cells in cochlea. Increases in CXCL1 was time-dependent in the spiral ganglion neurons and organ of Corti and was associated with progressive increases in CD45, CD68 and IBA1-positive immune cells. Trans-tympanic administration of SB225002, a chemical inhibitor of CXCR2 (receptor target for CXCL1) reduced immune cell migration, protected against cisplatin-induced hearing loss and preserved hair cell integrity. We show that SB225002 reduced the expression of
MeSH term(s)	Rats ; Animals ; Male ; Cisplatin/adverse effects ; Chemokine CXCL1/genetics ; Ototoxicity/drug therapy ; Ototoxicity/etiology ; Rats, Wistar ; NADPH Oxidases/metabolism ; Hearing Loss/chemically induced ; Hearing Loss/metabolism
Chemical Substances	Cisplatin (Q20Q21Q62J) ; SB 225002 ; Chemokine CXCL1 ; NADPH Oxidases (EC 1.6.3.-) ; Cxcl1 protein, rat
Language	English
Publishing date	2023-03-31
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1125948
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito